Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

125.90 -1.65 (-1.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharma Plc

< Previous 1 2 3 4 5 6 7 8 9 Next >
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill... 
Via FinancialNewsMedia
Exposures Product Safety
Jazz Pharmaceuticals' Return On Capital Employed Insights
  
Via Benzinga
'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst
 
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: 
Via Benzinga
Jazz Pharma, Sumitomo Pharma Ink Licensing Pact For Sleeping Disorder Candidate
 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread
The company just hired three new executives, likely putting a buyout in the rearview. 
Via Investor's Business Daily
Cannabis Stocks Struggle Through Q2 2022
An overview of how cannabis stocks fared in Q2 and what investors should understand about the space. 
Via Talk Markets
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. 
Via Benzinga
Brazilian Fund Invests $19M In US Cannabis Stocks
As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are... 
Via Benzinga
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea... 
Via Benzinga
Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced top-line results from the Phase 3 clinical trial investigating nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in individuals with... 
Via Benzinga
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
 
Via Benzinga
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises
The Swiss government confirmed that it will remove limitations on medical marijuana use, starting August 1st, 2022. 
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge... 
Via Benzinga
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL
Thomas Wesley Pentz, better known for his artistic name, Diplo, partnered with California cannabis beverage company Leisuretown, professional skateboarder Rob Dyrdek and cannabis supply chain company... 
Via Benzinga
4 Analysts Have This to Say About Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades 
Via Benzinga
Euro Food Agency Concerned About Health Effects Of CBD, Asks For More Research
The European Food Safety Authority (EFSA) is asking for more research on the effects of CBD on humans. 
Via Benzinga
North Carolina House Says Yes To Bill Allowing FDA-Approved THC Drugs, Will This Kill Full Medical Marijuana Legalization?
The North Carolina House passed Senate Bill 448, legalizing FDA-approved THC medications in a 92-9 vote, reported The Carolina Journal. 
Via Benzinga
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Battles Over CBD Hype Yet Again, This Time Warns Businesses Selling Illegal CBD For Food-Producing Animals
The Food and Drug Administration (FDA) sent letters to four CBD companies warning them against selling unauthorized CBD products for use in food-producing animals. Companies being warned are Haniel... 
Via Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
Exposures COVID-19
Jazz Pharmaceuticals Stock Sees Rising Price Performance With Jump To 81 RS Rating
Jazz Pharmaceuticals sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
Jazz Pharmaceuticals's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Jazz Pharmaceuticals (NASDAQ:JAZZ) posted Q1 earnings of $1.65 million, an increase from Q4 of 104.66%. Sales dropped to $813.72 million, a 9.26% decrease between... 
Via Benzinga
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval?
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. 
Via Benzinga
Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has completed the divestiture of Sunosi (solriamfetol) in the U.S. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.